Neuro Injury Specialists
- Transcranial Magnetic Stimulation (TMS)
- Neurofeedback Therapy
- Ketamine Therapy
Brooklyn, NY
Neurofeedback therapy in Brooklyn is offered at psychology practices, ADHD and autism clinics, and brain-performance centers, with neurology referrals often routed through NewYork-Presbyterian Brooklyn Methodist and Maimonides Medical Center. Demand reflects a dense, ethnically diverse, and uninsured-heavy population.
Neurofeedback uses EEG-based operant conditioning to train brain activity patterns, with variable evidence across ADHD, anxiety, PTSD, and post-concussion syndrome. It is FDA cleared as a biofeedback modality but not approved for specific psychiatric diagnoses. Clinics in Brooklyn, New York vary in protocol (standard EEG, LORETA, qEEG-guided) and in whether they combine with psychotherapy. New York State Department of Health's tight scope-of-practice enforcement shapes which professionals can deliver neurofeedback and bill insurance.
With neurofeedback clinics on Regenerated.com in Brooklyn, patients can compare clinician credentials (licensed psychologist vs technician), qEEG mapping, and realistic outcome framing.
Regulatory context
Repetitive transcranial magnetic stimulation (rTMS) is regulated as a Class II prescription device. The first 510(k) clearance went to NeuroStar in 2008 for treatment-resistant major depressive disorder. Subsequent clearances expanded the on-label scope to obsessive-compulsive disorder (BrainsWay deep TMS, 2018), smoking cessation (BrainsWay, 2020), anxious depression as an adjunct indication (2021), and migraine via single-pulse TMS devices such as eNeura SpringTMS and SAVI Dual. Biofeedback instruments are cleared under 21 CFR 882.1425 as Class II devices for relaxation training and stress reduction. EEG-based neurofeedback systems hold 510(k) clearances in the same category. Cranial electrotherapy stimulation, tDCS wellness devices, and many vagus nerve stimulation accessories sold direct to consumers are not cleared as medical devices, and clinical claims beyond cleared indications are off-label.
The New York State Office of Professional Medical Conduct investigates TMS clinics for supervision lapses, corporate practice violations, and off-label marketing. New York enforces a strong corporate practice of medicine doctrine and requires Professional Service Corporation or similar structures for clinical ownership. The New York attorney general pursues General Business Law Sections 349 and 350 actions against deceptive medical device advertising, including neurofeedback cure claims. Commercial insurers and New York Medicaid typically require documented treatment-resistant depression before covering TMS for major depressive disorder.
Explore related care